{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T19:40:06Z","timestamp":1739994006803,"version":"3.37.3"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-024-03024-0","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T21:41:36Z","timestamp":1735940496000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of Remote Regulatory Assessment (RRA) for Site Evaluations during the COVID-19 Pandemic: The USFDA\u2019s Office of Study Integrity and Surveillance (OSIS) Perspective"],"prefix":"10.1208","volume":"26","author":[{"given":"Tahseen","family":"Mirza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Fenty-Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clint","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Folian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Kassim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"key":"3024_CR1","unstructured":"FDA. Office of Study Integrity and Surveillance (OSIS) Workshop 2022: CDER Inspections of Good Laboratory Practice, Animal Rule, and Bioavailability\/Bioequivalence Study Sites, CDER Small Business Seminars Series, https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/office-study-integrity-and-surveillance-osis-workshop-2022-cder-inspections-good-laboratory-practice. Accessed 2 September 2023."},{"key":"3024_CR2","unstructured":"World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report 51. https:\/\/apps.who.int\/iris\/handle\/10665\/331475. Accessed 2 September 2023."},{"key":"3024_CR3","unstructured":"The White House. Notice on the Continuation of the National Emergency Concerning the Coronavirus Disease 2019 (COVID-19) Pandemic. :https:\/\/www.whitehouse.gov\/briefing-room\/presidential-actions\/2022\/02\/18\/notice-on-the-continuation-of-the-national-emergency-concerning-the-coronavirus-disease-2019-covid-19-pandemic-2\/. Accessed 2 September 2023."},{"key":"3024_CR4","unstructured":"European Medicine Agency (EMA). Guidance on remote GCP inspections during the COVID-19 pandemic. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guidance-remote-gcp-inspections-during-covid-19-pandemic_en.pdf. Accessed 2 September 2023."},{"key":"3024_CR5","unstructured":"Medicines and Healthcare products Regulatory Agency (MHRA). Guidance for industry on approaches to regulation we are taking during the COVID-19 outbreak 2020. https:\/\/www.gov.uk\/guidance\/mhra-regulatory-flexibilities-resulting-from-coronavirus-covid-19. Accessed 2 September 2023."},{"key":"3024_CR6","unstructured":"Churchward D. MHRA Good Practice (GxP) inspections during the COVID-19 outbreak. 2020. https:\/\/mhrainspectorate.blog.gov.uk\/2020\/03\/23\/mhra-good-practice-gxp-inspections-during-the-covid-19-outbreak\/. Accessed 2 September 2023."},{"key":"3024_CR7","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA), Japan. Procedure for Remote Inspection as a part of compliance inspection on drugs and regenerative medical products. 2020 https:\/\/www.google.com\/search?q=0.+https%3A%2F%2Fwww.+pmda.go.jp%2Ffiles%2F000238733.pdf. Accessed 2 September 2023."},{"key":"3024_CR8","unstructured":"International Coalition of Medicines Regulatory Authorities (ICMRA) COVID 19 Working Group. Reflections on the regulatory experience of remote approaches to GCP and GMP regulatory oversight during the COVID-19 Pandemic. 2021 https:\/\/www.icmra.info\/drupal\/sites\/default\/files\/2021-12\/remote_inspections_reflection_paper.pdf. Accessed 2 September 2023."},{"key":"3024_CR9","unstructured":"FDA. U.S. FDA\u2019s Ongoing Use of Inspectional Tools for Ensuring Access to Safe, Quality Food and Medical Products During the COVID-19 Pandemic. 2021. https:\/\/www.fda.gov\/news-events\/fda-voices\/fdas-ongoing-use-inspectional-tools-ensuring-access-safe-quality-food-and-medical-products-during. Accessed 2 September 2023."},{"key":"3024_CR10","unstructured":"FDA. Draft Guidance for Industry - Conducting Remote Regulatory Assessments Questions and Answers. 2024. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/conducting-remote-regulatory-assessments-questions-and-answers, Accessed February 2024."},{"key":"3024_CR11","unstructured":"FDA. Guidance for Industry - Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities. 2023. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/remote-interactive-evaluations-drug-manufacturing-and-bioresearch-monitoring-facilities. Accessed 2 January 2024."},{"key":"3024_CR12","doi-asserted-by":"publisher","unstructured":"Remote Regulatory Assessments of Bioavailability\/Bioequivalence Study Conduct by the Office of Study Integrity and Surveillance Editorial. 2024. https:\/\/link.springer.com\/article\/https:\/\/doi.org\/10.1208\/s12249-024-02967-8. Accessed 14 November 2024.","DOI":"10.1208\/s12249-024-02967-8"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-024-03024-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-024-03024-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-024-03024-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T19:26:40Z","timestamp":1739993200000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-024-03024-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,3]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["3024"],"URL":"https:\/\/doi.org\/10.1208\/s12249-024-03024-0","relation":{},"ISSN":["1530-9932"],"issn-type":[{"type":"electronic","value":"1530-9932"}],"subject":[],"published":{"date-parts":[[2025,1,3]]},"assertion":[{"value":"15 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest. The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the agency with which each author is affiliated.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}},{"value":"This article reflects the views of the authors and should not be construed to represent FDA\u2019s views or policies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"20"}}